Accord Healthcare opens new pharmaceutical facility in Newcastle
Fast growing pharmaceutical companies in the UK and Ireland, Accord Healthcare, has recently opened its new pharmaceutical facility in Fawdon, Newcastle. The move will expand the company’s portfolio and strengthen its supply chain and manufacturing operations.
With the aim to become the largest supplier of genetic medicines across the UK and Ireland, the new facility is situated over 22 acres and will create up to 500 new roles
“Fawdon will play a vital role in strengthening our manufacturing network, supported by our parent company Intas and our other UK sites. After seeing many domestic pharmaceutical manufacturing sites close, with production redirected overseas, this opening marks a vote of confidence in the UK’s attractiveness for high tech pharmaceutical manufacturing,” explained Dr James Burt, Executive Vice President, Europe & MENA, Accord Healthcare.
“We are committed to further strategic investment to support the site’s growth, adding value to the local economy in terms of jobs and exports, as well as furthering patient access to affordable medicines in both the UK and beyond.”
- Ping An Insurance Group is set to list its healthcare division
- Amazon, Berkshire Hathaway and JPMorgan Chase will partner on building new healthcare solutions
- New report highlights the growing trend of healthcare M&A’s
Previously owned by Sanofi before the company relocated to France, the facility will enable the creation of further roles upon the growth of pharmaceutical production, where it will export to over 25 countries across Europe.
Forming part of Accord Healthcare’s five-year strategy, the facility will support the growth of the UK economy, following on from its acquisition of Actavis UK and Ireland in 2017.
“The purchase of Fawdon preserves a legacy of manufacturing in Newcastle that spreads back over 50 years, added Dr Burt.
“We have invested heavily in the site. We have brought in state-of-the-art manufacturing equipment, we have upgraded the quality of the site so the medicines that are produced here are of a higher quality, and we have offered employment prospects back to a lot of people who were on this site previously.
“We are also investing in a laboratory to undertake discovery and development work so we can bring out the next generation of products at this site, and export them all over the world.”